| scholarly article | Q13442814 |
| P356 | DOI | 10.7326/0003-4819-112-9-674 |
| P698 | PubMed publication ID | 2334081 |
| P2093 | author name string | Klippel JH | |
| Boumpas DT | |||
| Balow JE | |||
| Barez S | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| lupus erythematosus | Q188297 | ||
| thrombocytopenia | Q585285 | ||
| P304 | page(s) | 674-677 | |
| P577 | publication date | 1990-05-01 | |
| P1433 | published in | Annals of Internal Medicine | Q564416 |
| P1476 | title | Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus | |
| P478 | volume | 112 |
| Q67774884 | A Randomized Trial of Plasmapheresis and Subsequent Pulse Cyclophosphamide in Severe Lupus: Design of the Lpsg Trial |
| Q33393399 | A case of spontaneous hemoperitoneum presenting as the initial manifestation of systemic lupus erythematosus |
| Q33360889 | A case report of the efficacy of apheresis for refractory autoimmune thrombocytopenia in a patient with systemic lupus erythematosus associated hemolytic anemia |
| Q33430964 | ANA Negative Systemic Lupus Erythematosus Leading to CTEPH, TTP-Like Thrombocytopenia, and Skin Ulcers |
| Q33411369 | Acute presentation of thrombocytopaenia in systemic lupus erythematosus is associated with a high mortality in South Africa |
| Q74389718 | Antiphospholipid syndrome |
| Q33503507 | Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy |
| Q41270539 | Cerebrovascular disease with antiphospholipid antibodies: immune mechanisms, significance, and therapeutic options |
| Q33394969 | Clinical assessment and management of cytopenias in lupus patients |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q34226984 | Cyclophosphamide for the treatment of systemic lupus erythematosus |
| Q54059237 | Effect of intravenous cyclophosphamide in systemic lupus erythematosus: relation to lymphocyte subsets and activation markers. |
| Q77689701 | Fatal interstitial pneumonia due to cytomegalovirus following cyclophosphamide treatment in a patient with systemic lupus erythematosus |
| Q33421876 | Haematological manifestations of lupus |
| Q33411323 | Hematological disorders in patients with systemic lupus erythematosus |
| Q40828770 | Indications for, and use of, cytotoxic agents in SLE. |
| Q36840240 | Kidney disease in systemic lupus erythematosus |
| Q90415019 | Lupus thrombocytopenia: pathogenesis and therapeutic implications |
| Q33339746 | Management of adult immune thrombocytopenia |
| Q33361803 | Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus |
| Q46925234 | Ovarian failure in SLE patients using pulse cyclophosphamide: comparison of different regimes |
| Q35918369 | Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide |
| Q36530185 | Pharmacological therapy for Wegener's granulomatosis. |
| Q33435137 | Prognostic significance of platelet count in SLE patients. |
| Q41582396 | Recognition and management of systemic lupus erythematosus |
| Q34398069 | Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus |
| Q53633371 | Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. |
| Q33386932 | Splenectomy for thrombocytopenia associated with systemic lupus erythematosus in 11 Chinese patients |
| Q47559187 | Splenectomy in systemic lupus erythematosus and autoimmune hematologic disease: a comparative analysis. |
| Q40506580 | Systemic lupus erythematosus--disease management |
| Q33384235 | The ITP syndrome: pathogenic and clinical diversity |
| Q72415990 | The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus |
| Q33429997 | Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients |
| Q42774619 | Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse |
| Q41207949 | Treatment Algorithms in Systemic Lupus Erythematosus |
| Q72002018 | Treatment of lupus glomerulonephritis with intravenous cyclophosphamide |
| Q32045005 | Treatment of lupus-induced thrombocytopenia with recombinant human interleukin-11. |
| Q33494745 | Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide |
| Q33406440 | Two cases of refractory thrombocytopenia in systemic lupus erythematosus that responded to intravenous low-dose cyclophosphamide |
| Q33893383 | Update on cyclophosphamide for systemic lupus erythematosus |
| Q44062952 | Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis |
Search more.